用生物剂治疗反应性关节炎的方法
Avarna Agarwal1, Debashis Maikap1, Prasanta Padhan2
1Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, Odisha, India.
Current rheumatology reports
|September 23, 2024
概括
生物药物,如抗TNF,抗IL17和抗IL6疗法,在标准治疗失败时,显示出对治疗耐火性反应性关节炎 (ReA) 的希望. 这些治疗方法通常是安全和有效的,尽管需要更多的受控试验.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 反应性关节炎 (ReA) 是一种炎症性关节疾病,通常是由远处的感染引发的.
- 对ReA的传统治疗可能不会在所有情况下都有效,因此需要探索替代疗法.
研究的目的:
- 综合最近关于生物药物的有效性和安全性的证据,作为反应性关节炎的治疗选择.
- 评估生物制剂在 ReA 耐火病例中的作用.
主要方法:
- 审查最近的研究,包括病例报告和病例系列,重点关注ReA的生物疗法.
- 对特定生物制剂的有效性和耐受性数据的分析.
主要成果:
- 生物药物,包括抗TNF (infliximab,adalimumab,etanercept),抗IL17 (secukinumab) 和抗IL6 (tocilizumab) 疗法,在耐火ReA中表现出有效性.
- 这些药物与显著的临床改善有关,并且通常耐受良好,主要不良事件发生率低.
- 当传统疗法不足时,生物药物为ReA提供了安全有效的治疗选择.
结论:
- 生物疗法代表了对常规治疗无反应性关节炎患者的可行和安全的治疗选择.
- 需要进一步进行精心设计的受控试验,以建立一个可靠的科学基础,用于管理难以治疗的REA病例的临床决策.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
01:29Autoimmune Disorders
395
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
395
01:24T Cell Types and Functions
960
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
960
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
01:17Drugs Used in Lower Respiratory Disorders: Overview
360
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
360
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K